Should I buy or sell Citius Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTXR shares. View CTXR analyst ratings or view top-rated stocks .

What is Citius Pharmaceuticals' stock price target for 2024?

1 analysts have issued 12 month target prices for Citius Pharmaceuticals' shares. Their CTXR share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 427.1% from the stock's current price. View analysts price targets for CTXR or view top-rated stocks among Wall Street analysts .

How have CTXR shares performed in 2024?

Citius Pharmaceuticals' stock was trading at $0.7565 at the start of the year. Since then, CTXR shares have increased by 0.3% and is now trading at $0.7589. View the best growth stocks for 2024 here .

When is Citius Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CTXR earnings forecast .

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) issued its earnings results on Wednesday, February, 14th. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.19.

When did Citius Pharmaceuticals' stock split?

Citius Pharmaceuticals's stock reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Bionano Genomics (BNGO) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Novan (NOVN) , ADMA Biologics (ADMA) , SCYNEXIS (SCYX) , Aeterna Zentaris (AEZS) , CBL & Associates Properties (CBL) , KushCo (KSHB) and Gran Tierra Energy (GTE) .

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CTXR

Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free CTXR Stock Alerts

$0.75

-0.05 (-6.34%)

(As of 04:00 PM ET)

Compare

Today's Range: $0.72
▼
$0.82
50-Day Range: $0.66
▼
$1.03
52-Week Range: $0.60
▼
$1.62

Volume: 1.67 million shs
Average Volume: 813,886 shs
Market Capitalization: $120.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Citius Pharmaceuticals alerts:

Citius Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 427.1% Upside
$4.00 Price Target
Short Interest: Bearish
7.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.21) to $0.09 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.74 out of 5 stars

Medical Sector

858th out of 918 stocks

Pharmaceutical Preparations Industry

392nd out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Citius Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Citius Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
7.81% of the outstanding shares of Citius Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Citius Pharmaceuticals has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Citius Pharmaceuticals has recently increased by 2.05%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Citius Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Citius Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CTXR.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Citius Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
11 people have searched for CTXR on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.
MarketBeat Follows
11 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.00% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 16.88% of the stock of Citius Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($0.21) to $0.09 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Citius Pharmaceuticals is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Citius Pharmaceuticals is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Citius Pharmaceuticals has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Citius Pharmaceuticals Stock (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

CTXR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CTXR Stock News Headlines

April 14, 2024 | seekingalpha.com

CTXR Citius Pharmaceuticals, Inc.

April 13, 2024 | americanbankingnews.com

Critical Analysis: Citius Pharmaceuticals (NASDAQ:CTXR) and Bio-Path (NASDAQ:BPTH)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 11, 2024 | prnewswire.com

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

April 4, 2024 | prnewswire.com

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

March 20, 2024 | finance.yahoo.com

CTXR Apr 2024 7.500 put

March 20, 2024 | finance.yahoo.com

CTXR May 2024 2.500 call

March 20, 2024 | edition.cnn.com

Citius Pharmaceuticals Inc

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 18, 2024 | msn.com

Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment

March 18, 2024 | markets.businessinsider.com

Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts

March 18, 2024 | finance.yahoo.com

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

March 7, 2024 | prnewswire.com

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

March 7, 2024 | prnewswire.com

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

February 26, 2024 | finance.yahoo.com

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

February 26, 2024 | prnewswire.com

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

February 23, 2024 | finance.yahoo.com

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

February 14, 2024 | prnewswire.com

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

February 14, 2024 | markets.businessinsider.com

Buy Rating for Citius Pharmaceuticals Backed by Resubmission of Lymphir BLA and Potential Orphan Drug Exclusivity

February 14, 2024 | finance.yahoo.com

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

February 14, 2024 | prnewswire.com

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

January 23, 2024 | finance.yahoo.com

Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors

January 4, 2024 | markets.businessinsider.com

Strong Buy Rating for Citius Pharmaceuticals Amid Promising Mino-Lok Progress and Strategic Oncology Spinout

January 2, 2024 | finanznachrichten.de

Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

January 2, 2024 | baystreet.ca

Citius Ekes out Gains as Trials End

January 2, 2024 | finance.yahoo.com

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update

January 2, 2024 | finance.yahoo.com

Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters

See More Headlines

Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CTXR
CUSIP: N/A
CIK: 1506251
Web: www.citiuspharma.com
Phone: (908) 967-6677
Fax: N/A
Employees: 22
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +433.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,540,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -41.63%
Return on Assets: -36.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.06
Quick Ratio: 5.06

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.58 per share
Price / Book: 1.29

Miscellaneous

Outstanding Shares: 159,100,000
Free Float: 135,231,000
Market Cap: $119.36 million
Optionable: Optionable
Beta: 1.45

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Leonard L. Mazur (Age 79)
Co-Founder, CEO, Chairman & Secretary
Comp: $676.88k
Mr. Myron Z. Holubiak (Age 77)
Co-Founder & Executive Vice Chairman
Comp: $641.25k
Dr. Myron S. Czuczman M.D. (Age 64)
Executive VP & Chief Medical Officer
Comp: $571.38k
Mr. Jaime Bartushak (Age 56)
Chief Business Officer, CFO & Chief Accounting Officer
Comp: $527.97k
Mr. Gary F. Talarico (Age 69)
Executive Vice President of Operations
Ms. Ilanit Allen
Vice President of Investor Relations & Corporate Communications
Dr. Alan Lader Ph.D.
Senior VP and Head of Clinical Operations & Quality Assurance
Mr. Dhananjay G. Wadekar (Age 70)
Senior Vice President of Business Strategy
Mr. Kelly Creighton Ph.D.
Executive Vice President of Chemistry, Manufacturing & Controls
Mr. Nikolas Burlew
Executive Vice President of Quality Assurance

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CTXR Stock Analysis - Frequently Asked Questions

Should I buy or sell Citius Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTXR shares.
View CTXR analyst ratings or view top-rated stocks.
What is Citius Pharmaceuticals' stock price target for 2024?: 1 analysts have issued 12 month target prices for Citius Pharmaceuticals' shares. Their CTXR share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 427.1% from the stock's current price.
View analysts price targets for CTXR or view top-rated stocks among Wall Street analysts.
How have CTXR shares performed in 2024?: Citius Pharmaceuticals' stock was trading at $0.7565 at the start of the year. Since then, CTXR shares have increased by 0.3% and is now trading at $0.7589.
View the best growth stocks for 2024 here.
When is Citius Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our CTXR earnings forecast.

How were Citius Pharmaceuticals' earnings last quarter?: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) issued its earnings results on Wednesday, February, 14th. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.19.
When did Citius Pharmaceuticals' stock split?: Citius Pharmaceuticals's stock reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Citius Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), KushCo (KSHB) and Gran Tierra Energy (GTE).
How do I buy shares of Citius Pharmaceuticals?: Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTXR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis

Citius Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Citius Pharmaceuticals Stock (NASDAQ:CTXR)

CTXR Stock Price History

CTXR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CTXR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™